Drugs News and Research

RSS

Specific class of drugs can reverse diet-induced obesity, fatty liver and diabetes in mice

Researchers at Karolinska Institutet may have found a new way to treat obesity and related disorders by targeting the cells' powerhouses, the mitochondria.

30 Apr 2024

Fentanyl inhalation linked to irreversible brain damage

Inhaling the synthetic opioid fentanyl may cause potentially irreversible brain damage (toxic leukoencephalopathy), warn doctors in the journal BMJ Case Reports, after treating a middle aged man found unresponsive in his hotel room after snorting the drug.

29 Apr 2024

Exhaled breath may be a promising avenue for antibiotic monitoring

Exhaled breath may be very promising alternative to blood for the therapeutic monitoring of antibiotics, the ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) will hear.

29 Apr 2024

New Kaposi sarcoma mouse model could be key to drug development

Researchers at UNC Lineberger Comprehensive Cancer Center, after decades of research efforts, have developed a mouse model of Kaposi sarcoma that could be key to the development of new drugs to treat the disease.

29 Apr 2024

Study reveals brown fat's built-in mechanism and potential obesity treatment

Brown fat, also known as brown adipose tissue (BAT), is a type of fat in our bodies that's different from the white fat around our belly and thighs that we are more familiar with.

29 Apr 2024

Ancient grains show promise for type 2 diabetes

A meta-analysis in the journal Nutrition, Metabolism and Cardiovascular Diseases finds that ancient grains like oats, brown rice, and millet may improve lipid profiles in type 2 diabetes patients, but variations in study designs call for further research to confirm these benefits.

29 Apr 2024

Parkinson’s UK invests £2.1 million in Neumora Therapeutics for preclinical testing of new Parkinson’s drug

Parkinson’s UK is investing £2.1million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation and protect brain cells in Parkinson’s. NLRP3 is a protein that plays a role in regulating a number of inflammatory processes that are believed to contribute to the damage to brain cells that underlies Parkinson’s.

27 Apr 2024

Harnessing immune enhancement to combat drug-resistant tuberculosis

Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the drug-resistant forms of the disease.

26 Apr 2024

Blood test predicts knee osteoarthritis eight years before tell-tale signs of the disease

A blood test successfully predicted knee osteoarthritis at least eight years before tell-tale signs of the disease appeared on x-rays, Duke Health researchers report.

26 Apr 2024

Japanese researchers test cardiac spheroids for heart regeneration in monkeys

Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function.

26 Apr 2024

Immune cells play a bigger role in high blood pressure than previously thought, opening doors for new treatments

A review in Nature Reviews Nephrology presents the association between immune cells and the development of hypertension, suggesting potential new therapeutic targets to mitigate the disease by managing inflammation.

26 Apr 2024

Study: Antibiotic use in moderate COVID-19 linked to clinical deterioration

Antibiotic treatment of adults hospitalized with moderate COVID-19 is associated with clinical deterioration, despite the drugs being given to over 40% of patients, according to new research being presented at this year's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April)

25 Apr 2024

Synthetic nanomaterial could be an effective tool for treating neurodegenerative diseases

A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer's and other neurodegenerative diseases.

25 Apr 2024

Medicare warning letters effectively cut antipsychotic prescribing for dementia patients

Warning letters from Medicare can safely cut prescribing of a powerful but risky antipsychotic, according to a new study at Columbia University Mailman School of Public Health.

25 Apr 2024

MIT study reveals circadian impact on drug metabolism in engineered livers

Giving drugs at different times of day could significantly affect how they are metabolized in the liver, according to a new study from MIT.

25 Apr 2024

Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval

Clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine announces that it has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application for ISM3412, a small molecule inhibitor of MAT2A for the potential treatment of MTAP deleted cancers designed with Insilico's generative AI platform.

25 Apr 2024

Research reveals undertreatment of women with heart disease

Women with heart disease are less often treated with cholesterol-lowering drugs than men, according to research presented today at ESC Preventive Cardiology 2024, a scientific congress of the European Society of Cardiology (ESC).

25 Apr 2024

Researchers identify a ‘gene module’ involved in both depression and cardiovascular disease

Depression and cardiovascular disease (CVD) are serious concerns for public health. Approximately 280 million people worldwide have depression, while 620 million people have CVD. It has been known since the 1990s that the two diseases are somehow related.

25 Apr 2024

New system personalizes chemotherapy doses for cancer patients

When cancer patients undergo chemotherapy, the dose of most drugs is calculated based on the patient's body surface area. This is estimated by plugging the patient's height and weight into an equation, dating to 1916, that was formulated from data on just nine patients.

24 Apr 2024

Study links acid-reducing drugs to increased risk of migraine

People who take acid-reducing drugs may have a higher risk of migraine and other severe headache than people who do not take these medications, according to a study published in the April 24, 2024, online issue of Neurology Clinical Practice, an official journal of the American Academy of Neurology.

24 Apr 2024